

Press Release

Abliva AB (publ), 556595-6538
29 June 2023 14:30:00 CEST - Lund,
Sweden



Abliva presents at UMDF Mitochondrial Medicine 2023

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present at UMDF's Mitochondrial Medicine Symposium, the largest US conference on mitochondrial medicine, being held in Charlotte, North Carolina, from June 28 to July 1, 2023.

The U.S. patient advocacy group, United Mitochondrial Disease Foundation (UMDF), hosts an annual meeting focused on mitochondrial medicine, this year in Charlotte, North Carolina. Similar to the European meeting on mitochondrial disease, Euromit, this year held in Bologna, Italy, in June, UMDF's Mitochondrial Medicine Symposium brings mitochondrial disease researchers, physicians, clinical trial experts and patient advocacy groups together to discuss the latest advances in mitochondrial research and clinical development. In addition, UMDF has an extensive program for patients and families.

During the meeting, the Abliva team and collaborators will present data from the fatigue endpoint validation study, experimental data from the company's KL1333 program, as well as experimental data from the NV354 program. In addition, Abliva's Chief Medical Officer, Magnus Hansson, will provide an update on the company's ongoing, potentially registrational, Phase 2 study, the FALCON study. The following posters will be presented:

- FALCON: A Randomized, Placebo-Controlled Study of the Efficacy of KL1333 in Adult Patients with Primary Mitochondrial Disease.
Magnus J. Hansson, Fia Ence, Dag Nesse, Eskil Elmér, Ellen Donnelly.
- Development and Validation of a Mitochondrial Disease-Specific Fatigue Questionnaire.
Amel Karaa, Roxy Bahar, Sarah Clifford, Gráinne Gorman, Magnus J. Hansson.
- Quinone Compounds in Primary Mitochondrial Disease: Characterization of Enzymatic NAD⁺/NADH Modulation In Vitro and Translation to Acute Metabolic Effects in Human Cells.
Magnus J. Hansson, Shilan Alsaied, Shusuke Sekine, Irene Yee, Imen Chamkha, Sonia Simón Serrano, Eleonor Åsander Frostner, Lee Webster, Steven J. Moss, Eskil Elmér.
- Succinate Does Not Increase Reactive Oxygen Species Generation in Phosphorylating Human Mitochondria.
Irene Yee, Alina Lenzer, Shusuke Sekine, Tianshi Liu, Imen Chamkha, Eskil Elmér, Johannes Ehinger.

Additional information about UMDF Mitochondrial Medicine 2023 can be found on the website for the event (<https://www.umdf.org/symposium/>).

Press Release

Abliva AB (publ), 556595-6538
29 June 2023 14:30:00 CEST - Lund,
Sweden



For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: <https://abliva.com/posts/news-subscription/>
Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>
Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is in clinical trials. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Abliva presents at UMDf Mitochondrial Medicine 2023](#)